| Cancer |
0 |
0.93 |
| Breast Cancer |
0 |
0.91 |
| Cancer Risk |
0 |
1 |
| Esophageal Cancer |
0 |
0.7 |
| Kidney Cancer |
0 |
0.7 |
| Noncolorectal Gastrointestinal Cancer |
0 |
0.69 |
| Ovarian Cancer |
0 |
0.69 |
| Gastric Cancer |
0 |
0.68 |
| Renal Cell Carcinoma |
0 |
0.68 |
| Otolaryngology |
0 |
0.66 |
| Prostate Cancer |
0 |
0.57 |
| Bladder Cancer |
0 |
0.56 |
| Acne |
0 |
0.29 |
| Skin and Soft Tissue Infection |
0 |
0.19 |
| Rosacea |
0 |
0.17 |
| Breast |
0 |
0.15 |
| Hirsutism |
0 |
0.12 |
| Meta-Analysis |
0 |
0.12 |
| Androgenetic Alopecia |
0 |
0.08 |
| Heart Failure (HF) |
0 |
0.08 |
| Alopecia |
0 |
0.07 |
| Conn Syndrome |
0 |
0.06 |
| Hypertension |
0 |
0.06 |
| Ascites |
0 |
0.04 |
| Bladder |
0 |
0.04 |
| Clinical Guidelines |
0 |
0.04 |
| Edema |
0 |
0.04 |
| Endocrine Society |
0 |
0.04 |
| Esophagus |
0 |
0.04 |
| Europe |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Grant |
0 |
0.04 |
| Heart |
0 |
0.04 |
| Hyperaldosteronism |
0 |
0.04 |
| Kidney |
0 |
0.04 |
| Off-Label Use |
0 |
0.04 |
| Prostate |
0 |
0.04 |
| Skin Care |
0 |
0.04 |
| Social Determinants of Health |
0 |
0.04 |
| Steroids |
0 |
0.04 |
| Texas |
0 |
0.04 |
| Transgender |
0 |
0.04 |